12 Dec 2023 – Nova MSC Berhad (“Nova MSC” or “the Company”), the parent company of EyRIS Pte Ltd (“EyRIS”), proudly announces that its state-of-the-art Artificial Intelligence (“AI”) tool, SELENA+, has been selected for the Sultanate of Oman’s National Diabetic Retinopathy (DR) Screening Program. This significant step underscores the global recognition and trust in EyRIS’s AI-driven solutions for enhancing healthcare outcomes.
SELENA+, a pioneering AI technology, has shown remarkable efficiency and accuracy in automated retinal image analysis. Its integration into Oman’s healthcare framework marks a major leap forward in managing and preventing diabetes-related complications, particularly diabetic retinopathy. This initiative signifies Nova MSC’s first venture into Oman and aligns with the nation’s commitment to adopting advanced healthcare solutions.
Mr Nazeroll Kasim, Executive Director of Nova MSC, said, “This collaboration marks a significant milestone in our journey towards revolutionising healthcare with AI technology. SELENA+’s selection is a testament to its technological prowess and our team’s dedication to creating solutions that make a real difference in people’s lives. We are eager to see how our technology will help in the early detection and management of diabetic retinopathy, contributing to better health outcomes in Oman.”
SELENA+’s success in Oman follows its groundbreaking achievements in Singapore’s National DR Screening Program (SiDRP). In September 2020, EyRIS was awarded a 5-year contract for SELENA+ deployment, making it the world’s first real-world AI medical device adoption in a national screening program.
Since July 2021, SELENA+ has been seamlessly integrated into Singapore’s public sector, with a specific focus on screening all participants enrolled in the Singapore Integrated Diabetic Retinopathy Program (SiDRP). As an advanced artificial intelligence tool, SELENA+ exhibits the capability to identify vision-threatening diabetic retinopathy, potential glaucoma cases, and age-related macular degeneration. Notably, the accuracy of SELENA+ aligns closely with the established standard of care.
Mr. Nazeroll commented on the global impact, “SELENA+’s nationwide deployment in Singapore and now in Oman is a proud testimony for the roll-out viability our AI innovations in medical diagnostics. By taking the lead in the respective ASEAN and Middle East regions, these successes demonstrate our ability to harness advanced technology in tackling global healthcare challenges and serve as springboard to other aspiring countries.”
He added, “The Oman project exemplifies our significant business-to-government engagement and positions Nova MSC as a leader in AI healthcare innovation. This initiative serves as a model for future collaborations, where our technologies can integrate into national healthcare strategies, showcasing our dedication to advancing global healthcare technology.”
Please direct all queries related to this article to Marketing at firstname.lastname@example.org
Comments are closed.